Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference
TORONTO–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry... Read more.
Nuveen Churchill Direct Lending Corp. Announces Second Quarter 2025 Results
Reports Second Quarter Net Investment Income of $0.46 per Share Declares Third Quarter Regular Distribution of $0.45 per Share NEW YORK–(BUSINESS WIRE)–Nuveen... Read more.
Acacia Research Corporation Reports Second Quarter 2025 Financial Results
Total Revenue of $51.2 million for the Quarter GAAP Net Loss of ($3.3) million and GAAP Diluted EPS of ($0.03) for the Quarter Adjusted Net Loss1 of ($5.9) million... Read more.
Extreme Networks Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Q4 revenue up 20% year-over-year, marking fifth consecutive quarter of sequential growth SaaS ARR up 24% YoY MORRISVILLE, N.C.–(BUSINESS WIRE)–Extreme... Read more.
NRG Energy, Inc. Reports Second Quarter Results and Reaffirms 2025 Financial Guidance
Strong financial and operating results; reaffirming 2025 guidance ranges and capital allocation Signed 295 MW of premium, long-term retail agreements for data centers... Read more.
FiscalNote Refinances Senior Secured Term Loan with New Four Year Facility Maturing in 2029 to Drive Long-Term Operating Flexibility
FY25 Guidance Reaffirmed, Reflecting Confidence in Accelerating Momentum from Product-Led Growth Strategy and Ongoing Operational Discipline WASHINGTON–(BUSINESS... Read more.
Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative... Read more.
Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Seasoned Commercial Hematology and Oncology Leader Harout Semerjian Appointed as President and CEO Achieved $49.0 million in RYTELO® net product revenue in Q2 2025... Read more.
Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B
– Proof-of-activity now established for PBGENE-HBV, the first and only clinical modality designed to eliminate covalently closed circular DNA (cccDNA) and... Read more.
MarketAxess Announces Trading Volume Statistics for July 2025
12% Growth in Total Credit ADV Driven by 21% Growth in Combined Emerging Markets and Eurobonds ADV NEW YORK–(BUSINESS WIRE)–MarketAxess Holdings Inc.... Read more.